Thomas Prebet, MD, PhD, Yale School of Medicine, previews recent advancements and treatment options for acute myeloid leukemia (AML) patients with TP53, IDH, and FLT3 mutations. Dr. Prebet hopes to see new data on combination treatments and rising new therapies for AML at the American Society of Hematology 2020 conference. Since relapse is very common, Dr. Prebet looks forward to new data on targeted therapies for CD47, TP53, and CD123.